Clinical Trials · NCT02773368
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 420
- Start date
- May 2016
- Locations
- 88 sites, 11 countries
- Primary endpoint
- Change in HbA1c (Glycosylated Haemoglobin)